论文部分内容阅读
目的:评价短期应用利维爱治疗围绝经期妇女更年期综合征的疗效及安全性。方法:选择围绝经期有更年期综合征症状的妇女40例,随机分为两组各20例。A组给予利维爱2.5 mg/天,B组给予利维爱1.25 mg/天,连续用药6个疗程,观察用药前后改良Kuppereman评分、血清促卵泡素(FSh)、雌二醇(E2)、血脂、子宫内膜厚度等的变化。结果:A组用药1、3、6个月后,B组用药3、6个月后Kuppereman评分均明显降低,与治疗前相比差异均具有统计学意义(P<0.01);而B组用药1个月,Kuppereman评分与治疗前相比差异无统计学意义(P>0.05);A组用药3、6个月后,B组用药6个月后,妇女血Fsh下降,E2升高,与用药前相比差异均具有统计学意义(P<0.01);而A组用药1个月后,B组用药1、3个月后血Fsh、E2分别与治疗前相比差异均无统计学意义(P>0.05);A、B组用药前与用药6个月后总胆固醇、甘油三酯、高密度酯蛋白均降低,差异具有统计学意义(P<0.01);而用药前后血糖、低密度酯蛋白比较差异均无统计学意义(P>0.05);A、B组用药6个月后与用药前相比子宫内膜均增厚,差异具有统计学意义(P<0.01),但宫腔镜及内膜活检均在正常范围内。结论:短期利维爱治疗围绝经期妇女更年期综合征是安全有效的,其剂量可个体化选择。
OBJECTIVE: To evaluate the efficacy and safety of short-term use of leviotherapy in the treatment of menopause syndrome in perimenopausal women. Methods: Forty women with climacteric menopause syndrome were randomly divided into two groups of 20 cases each. Group A received levofloxacin 2.5 mg / day, Group B received levovir 1.25 mg / day for 6 courses. The Kuppereman score, FSh, E2, Endometrial thickness and other changes. Results: After 1, 3 and 6 months of treatment, the Kuppereman scores of group B were significantly decreased 3 and 6 months after treatment, with statistical significance (P <0.01), while those in group B After 1 month, the Kuppereman score was not significantly different from that before treatment (P> 0.05). After 3 months and 6 months of treatment in group A, the Fsh of women decreased and E2 increased after 6 months of treatment, Compared with before treatment, the differences were statistically significant (P <0.01); while in group A, there was no significant difference in Fsh and E2 between 1 and 3 months after treatment (P> 0.05). The total cholesterol, triglyceride and high density ester protein in group A and group B before treatment and after 6 months of treatment were significantly lower than those before treatment (P <0.01) (P> 0.05). In group A and group B, endometrial thickness was thicker than that before treatment (P <0.01), but there was no significant difference between the two groups Mirror and endometrial biopsy are in the normal range. Conclusion: Short-term Levi treatment of perimenopausal women menopause syndrome is safe and effective, the dose can be individualized choice.